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Machine learning derivation of four
computable 24‑h pediatric sepsis phenotypes
to facilitate enrollment in early personalized
anti‑inflammatory clinical trials
Yidi Qin1, Kate F. Kernan2, Zhenjiang Fan3, Hyun‑Jung Park1, Soyeon Kim4, Scott W. Canna4, John A. Kellum2,
Robert A. Berg5, David Wessel6, Murray M. Pollack6, Kathleen Meert7,8, Mark Hall9, Christopher Newth10,
John C. Lin11, Allan Doctor11, Tom Shanley13, Tim Cornell14, Rick E. Harrison12, Athena F. Zuppa4, Russell Banks13,
Ron W. Reeder13, Richard Holubkov13, Daniel A. Notterman14,15, J. Michael Dean13 and Joseph A. Carcillo2*

Abstract
Background: Thrombotic microangiopathy-induced thrombocytopenia-associated multiple organ failure and hyper‑
inflammatory macrophage activation syndrome are important causes of late pediatric sepsis mortality that are often
missed or have delayed diagnosis. The National Institutes of General Medical Science sepsis research working group
recommendations call for application of new research approaches in extant clinical data sets to improve efficiency of
early trials of new sepsis therapies. Our objective is to apply machine learning approaches to derive computable 24-h
sepsis phenotypes to facilitate personalized enrollment in early anti-inflammatory trials targeting these conditions.
Methods: We applied consensus, k-means clustering analysis to our extant PHENOtyping sepsis-induced Multiple
organ failure Study (PHENOMS) dataset of 404 children. 24-hour computable phenotypes are derived using 25 avail‑
able bedside variables including C-reactive protein and ferritin.
Results: Four computable phenotypes (PedSep-A, B, C, and D) are derived. Compared to all other phenotypes, Ped‑
Sep-A patients (n = 135; 2% mortality) were younger and previously healthy, with the lowest C-reactive protein and
ferritin levels, the highest lymphocyte and platelet counts, highest heart rate, and lowest creatinine (p < 0.05); PedSepB patients (n = 102; 12% mortality) were most likely to be intubated and had the lowest Glasgow Coma Scale Score
(p < 0.05); PedSep-C patients (n = 110; mortality 10%) had the highest temperature and Glasgow Coma Scale Score,
least pulmonary failure, and lowest lymphocyte counts (p < 0.05); and PedSep-D patients (n = 56, 34% mortality) had
the highest creatinine and number of organ failures, including renal, hepatic, and hematologic organ failure, with the
lowest platelet counts (p < 0.05). PedSep-D had the highest likelihood of developing thrombocytopenia-associated
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multiple organ failure (Adj OR 47.51 95% CI [18.83–136.83], p < 0.0001) and macrophage activation syndrome (Adj OR
38.63 95% CI [13.26–137.75], p < 0.0001).
Conclusions: Four computable phenotypes are derived, with PedSep-D being optimal for enrollment in early per‑
sonalized anti-inflammatory trials targeting thrombocytopenia-associated multiple organ failure and macrophage
activation syndrome in pediatric sepsis. A computer tool for identification of individual patient membership (www.
pedsepsis.pitt.edu) is provided. Reproducibility will be assessed at completion of two ongoing pediatric sepsis studies.
Keywords: Severe sepsis, Multiple organ failure, Immunoparalysis-associated multiple organ failure,
Thrombocytopenia-associated multiple organ failure, Macrophage activation syndrome, Sequential multiple organ
failure, Hyperferritinemic sepsis

Introduction
Severe sepsis defined by infection and organ failure
contributes to 1 of 5 deaths globally, with 3 million per
year occurring in children [1]. While there is evidence
that sepsis mortality increases if treatment is delayed [2,
3], several studies in high-income countries where rapid
access to intensive care support has been provided, have
demonstrated patterns of mortality even in previously
healthy children with timely treatment [4–6]. This
indicates that dysregulated host immune activation could
be targetable in the pediatric intensive care unit (PICU)
[7–19]. Among such conditions are immune depression
leading to immunoparalysis-associated MOF (IPMOF)
[7, 8, 14, 15], thrombotic microangiopathy leading to
thrombocytopenia-associated MOF (TAMOF) [9, 10,
14, 15], and hyperinflammatory macrophage activation
syndrome (MAS) driven either by uncontrolled
lymphoproliferation manifest as sequential liver failureassociated MOF (SMOF) [11, 14, 15] or by macrophage
activation without lymphoproliferation manifest as
combined hepatobiliary dysfunction and disseminated
intravascular coagulation [12–15]. In the PHENOtyping
pediatric sepsis-induced Multiple organ failure Study
(PHENOMS) [15], we previously reported that these
conditions developed at a median of day 3 to 7 of sepsis,
with TAMOF and MAS demonstrating 46% mortality,
and IPMOF 16% mortality [15]. Anti-inflammatory
therapies used to reverse TAMOF and MAS include
methylprednisolone,
intravenous
immunoglobulin
(IVIG) and plasma exchange [9, 16–19]. Our clinical
trials challenge is to identify these at-risk children for
early enrollment when personalized therapies have their
greatest likelihood to succeed.
The NIGMS (https://loop.nigms.nih.gov/2019/05/
recommendations) sepsis research working group
recommendations call for use of new clinical research
approaches in extant clinical data sets to characterize
septic patients and improve the efficiency of early trials
of new sepsis treatments. In this manuscript, we test the
hypothesis that machine learning methods previously
used in adults [20] could be applied to available bedside

clinical variables including C-reactive protein and ferritin
in the extant PHENOMS dataset [15] to derive 24-h
computable sepsis phenotypes [20–22] that identify
children at risk for development of TAMOF and MAS
for enrollment in early personalized anti-thrombotic and
anti-inflammatory clinical trials.

Materials and methods overview
We analyzed blood samples and clinical data obtained
from our previously published PHENOMS study [15].
Approval was obtained from The University of Utah
Institutional Review Board, Central IRB # 70976. Written
informed consent was obtained from one or more
parents/guardians for each child. Assent was garnered
when the child was able. Patients were enrolled from
2015–2017. The CONSORT diagram (Additional file 1:
Fig. S1) and details of the parent clinical study protocol
have been previously published [15]. Three consented
and enrolled children who were excluded from reporting
in the parent study manuscript because there was a cap
of 81 patients to maximize equalization in enrollment
among the centers are additionally included in this
machine learning manuscript. Children qualified for
enrollment in PHENOMS if they (1) were between the
ages of 44 weeks gestation to 18 years of age; (2) were
suspected of having infection meeting two or more of
four systemic inflammatory response criteria [23]; (3) had
one or more organ failures [24]; and (4) had an indwelling
arterial or central venous catheter [15]. Children were
excluded from enrollment if there was not a commitment
to aggressive PICU care. Clinical data and blood samples
measuring C-reactive protein, Ferritin, sFASL, ADAMTS
13 activity, and whole blood ex vivo TNF response to
endotoxin were obtained on day one and twice weekly
until 28 days in the PICU in the parent study [15].
The parent study was not designed with a plan for performing post hoc machine learning analysis. To minimize
inherent selection bias, we set the a priori elements and
derived findings before performing the machine learning analysis. The a priori elements included all data available and previously published in the parent study [15], all
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patients enrolled in the CONSORT diagram (Additional
file 1: Fig. S1), and additional measurements of multiple cytokines. The derived machine learning approach
methods and findings are illustrated in Fig. 1 and were
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designed and set a priori to address the following recommendations of DeMerle and colleagues [25].
DeMerle et al. suggested that derived machine learning phenotypes need to be clinically relevant, biologically

Fig. 1 Overview of machine learning, visualization, and statistical methods applied to the PHENOMS pediatric sepsis data set
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plausible, nonsynonymous, treatment responsive, and
reproducible if they are to provide a ‘path forward’ in trial
design [25]. Our statistical approach toward these goals
is shown in Fig. 1. To derive nonsynonymous computable
phenotypes, we applied unsupervised clustering methods
[26] to a priori clinical and laboratory data available at the
first 24 h of PICU stay with severe sepsis (Table 1, Fig. 2,
Additional file 1: Tables S1–S4, Additional file 1: Figs.
S2–S7). To understand biological plausibility and clinical
relevance, we examined correlations between the derived
computable phenotypes and the a priori diagnoses, infections, and inflammatory cytokine responses (Table 2,
Fig. 3, Additional file 1: Tables S5–S8, Additional file 1:
Figs. S8–S10), and a priori organ failure and mortality
outcomes (Table 2, Figs. 4 and 5, Additional file 1: Tables
S9–S11, Additional file 1: Figs. S11–S15). We further
examined correlations between the derived computable
phenotypes and the a priori elements immunoparalysisassociated MOF (immune depression defined by ex vivo
TNF response to endotoxin < 200 pg/ml beyond three
days with two or more organ failures) [8, 15, 27], thrombocytopenia-associated MOF (thrombotic microangiopathy defined by ADAMTS13 activity < 57% of control with
platelet count < 100,000/mm3 and acute kidney injury
with oliguria and serum creatinine > 1 mg/dL) [9, 15, 27],
sequential liver failure-associated MOF (lymphoproliferative disease associated with liver failure defined by
soluble FAS ligand > 200 pg/mL with PaO2/FiO2 < 300
and mechanical ventilation followed seven days or later
with serum ALT > 100 U/L and bilirubin > 1 mg/dL) [11,
15, 27], and macrophage activation syndrome (hyperinflammation defined by ferritin > 500 ng/mL with platelet
count < 100 K/mm3, INR > 1.5, ALT > 100 U/L and bilirubin > 1 mg/dL) (Table 2, Additional file 1: Table S9, Additional file 1: Fig. S14) [12, 13, 15, 27].
In exploratory preliminary analysis of a priori antiinflammatory treatments, we assessed interactions with
one another among the derived phenotypes in patients
who received any of these anti-inflammatory therapies. We applied elastic net regression analysis to any a
priori organ support and anti-inflammatory therapies
used by bedside clinicians that were found in univariable analysis to be associated with survival in any of the
derived computable phenotypes or in the population as
a whole (p < 0.05) (Fig. 6, Additional file 1: Tables S12 and
S13, Additional file 1: Fig. S15) [28]. Because elastic net
regression analysis does not allow for calculation of 95%
confidence intervals, we further applied logistic regression analysis to any anti-inflammatory therapy interactions associated with mortality odds ratio < 0.1 in the
elastic net regression model (Additional file 1: Tables
S14–S17).
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Candidate clinical variables for phenotyping

Of the 52 bedside variables collected a priori in the
parent study, only 25 were available at 24 h with less
than 20% missingness and less than 60% correlation
with any other variable (Table 1, Additional file 1: Tables
S1 and S2, Additional file 1: Fig. S2). These included
demographic variables (age, gender, ethnicity, previous
health status, post-op status), PRISM-related vital
signs and laboratory values (systolic blood pressure,
heart rate, Glasgow Coma Scale Score, hemoglobin,
creatinine, platelet count, intubation status), markers
of inflammation (temperature, number of SIRS criteria,
lymphocyte count, C-reactive protein level, ferritin level),
and organ failures (Central Nervous System = Glasgow
Coma Scale < 12 not explained by use of sedation;
Cardiovascular = Requirement for vasoactive agents
for Systolic Blood Pressure < 5th percentile for age;
Respiratory = PaO2/FiO2 ratio < 300 requiring mechanical
ventilation; Renal = oliguria and serum creatinine > 1 mg/
dL; Hepatic = ALT > 100 and Bilirubin > 1 mg / dL;
Hematologic = Platelet Count < 100 K and INR > 1.5) [11,
15, 27]. For each a priori PRISM variable we extracted
the most abnormal value in the first 6 h. For each a priori
inflammation and organ failure variable we extracted the
most abnormal value within 24 h. Consensus k-means
clustering models were used to derive 24-h computable
phenotypes using these 25 variables because the method
provides nonsynonymous agnostic clusters and has a
1000 iterations step to assure internal consistency [20].
Specific chronic illnesses and present illnesses were
not included in the derived 25-element phenotype
assessment model. Specific sites of infection (blood, lung,
urine) and etiologies of infection (bacterial, fungal, viral,
and culture negative) were not included in the derived 25
element phenotype assessment model because they were
not reliably available in the first 24 h.
Biological correlates and outcomes

We studied 33 a priori biomarkers including 31 cytokines
and two functional assays concomitantly measured one
day only, at day 1 of severe sepsis; whole blood ex vivo
TNF response to endotoxin as a marker of immune
depression [7, 8, 15, 27], and ADAMTS 13 activity as a
marker of microvascular thrombosis in the presence of
thrombocytopenia [7, 15, 27]. Plasma for cytokine measurement was divided into three assays. IL-18, IL-18BP,
and CXCL9 were measured at 25-fold dilution [29].
IFN α, sCD163, and IL-22 were measured by Bioplex
inflammatory flex-set assay per manufacturer’s instructions (Bio-Rad). The remainder were measured by Bioplex Group I/II flex-set assay (Bio-Rad). All cytokines
were measured on a BioPlex 200 System (Bio-Rad). The
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Table 1 Demographic and day 1 clinical characteristics of the four phenotypes
Characteristic1
No. of patients, N (%)

Total
404 (100)

PedSep-A

PedSep-B

PedSep-C

PedSep-D

136 (34)

102 (25)

110 (27)

56 (14)

Demographic
Age years* mean (SD)

7 (6)

8 (6)a

3 (4)

10 (5)a,b

8 (6)a

59 (53.6)

34 (60.7)

34 (33.3)

51 (46.4)

22 (39.3)

12 (11.8)

23 (20.9)

4 (7.1)

86 (78.2)

51 (91.1)

68 (66.7)a

Male* N (%)

224 (55.4)

Female* N (%)

180 (44.6)

73 (53.7)

Hispanic* N (%)

67 (16.6)

28 (20.6)

Non-Hispanic* N (%)

323 (80.0)

100 (73.5)

86 (84.3)

Previous healthy* N (%)

180 (44.6)

Surgery* N (%)

49 (12.1)

63 (46.3)

96 (70.6)b,c,d
6 (4.4)

28 (27.5)

37 (33.6)

19 (33.9)

19 (18.6)a

12 (10.9)

12 (21.4)a

Organ dysfunction
SIRS criteria, mean (SD)2

2.9 (0.8)

2.9 (0.8)

3.0 (0.8)

2.8 (0.8)

3 (0.8)

OFI* mean (SD)3

1.8 (0.9)

1.4 (0.5)

2.1 (0.6)a,c

1.4 (0.6)

3.1 (1.0)a,b,c

11.7 (10.4)

7.3 (7.3)

13.2 (11.5)a

15.2 (10.4)a

Inflammation
CRP mg/dL* mean (SD)
Low temperature °C* mean

36.6 (1.2)

36.7 (0.9)

High temperature °C* mean

37.8 (1.3)

37.8 (1.1)

ALC/mm3* median (IQR)
Ferritin ng/mL* median (IQR)

1.2 (0.6–2.1)

b

13.1 (11.2)a

36.0 (1.6)

a,b,d

37.1 (0.9)

36.3 (1.0)

37.4 (1.3)

38.3 (1.2)a,b,d

37.8 (1.4)

1.9(1.3–3.2)b,c,d

1.1(0.6–1.9)c

1.1(0.6–2.1)c

0.6 (0.2–1.0)
a

a,b

405(176.2–1485.7)

610 (221.1–2482.0)a,b

218 (98.0–625.3)

125(69.8–207.8)

223(116.5–544.2)

Pulmonary OFI* N (%)

270 (66.8)

108 (79.4)c

87 (85.3)c

37 (33.6)

38 (67.9)c

Intubation* N (%)

211 (52.2)

72 (52.9)c

94 (92.2)a,c,d

15 (13.6)

30 (53.6)c

Pulmonary

Cardiovascular or hemodynamic
155.4 (31.3)

168.1 (30.8)b,c,d

146.5 (27.9)

Systolic blood pressure*, mean (SD) mmHg

81.9 (19.3)

85.0 (15.7)b

74.8 (22.0)

Cardiovascular OFI* N (%)

284 (70.3)

63 (46.3)

92 (90.2)a

85 (77.3)a

44 (78.6)a

0.3 (0.2–0.4)

0.6 (0.4–1.0)a

0.6 (0.4–0.7)a

1.4 (0.6–2.6)a,b,c

Heart rate bpm* mean (SD)

150.4 (27.6)
86.3 (17.2)b

150.6 (35.8)
78.9 (21.9)

Renal
Creatinine mg/dL* median (IQR)

0.5 (0.3–0.8)

Renal OFI* N (%)

30 (7.4)

0 (0.0)

0 (0.0)

0 (0.0)

30 (53.6)a,b,c

40 (9.9)

3 (2.2)

9 (8.8)

11 (10.0)a

17 (30.4)a,b,c

Hepatic
Hepatic OFI* N (%)
Hematologic
Hemoglobin g/dL* mean (SD)
Platelets K/mm3* mean (SD)
Hematologic OFI* N (%)

9.8 (2.0)
171.1 (123.2)

10.1 (1.8)b,d
260.1 (122.0)b,c,d

9.4 (2.1)

10.2 (2.1)b,d

9.1 (1.8)

154.3 (95.1)c,d

118.8 (83.5)d

88.2 (108.0)

39 (9.7)

0 (0.0)

0 (0.0)

Glasgow Coma Scale Score* mean (SD)4,5

8.7 (5.3)

8.5 (5.2)b

4.7 (3.4)

CNS OFI N (%)

54 (13.4)

12 (8.8)

24 (23.5)a,c

8 (7.3)a,b

31 (85.7)a,b,c

Neurologic
13.2 (3.1)a,b,d

7.9 (5.5)b

6 (5.5)

12 (21.4)c

IQR interquartile range, SIRS systemic inflammatory response syndrome, OFI organ failure index, ALC absolute lymphocyte count, CNS central nervous system
SI conversion factors: to convert alanine transaminase and aspartate aminotransferase to μkat/L, multiply by 0.0167; bilirubin to μmol/L, multiply by 17.104; C-reactive
protein to nmol/L, multiply by 9.524; creatinine to μmol/L, multiply by 88.4
*Comparisons across all 4 computable phenotypes were performed using the Kruskal–Wallis test, the χ2 test, or the Fisher’s exact test (Additional file 1: Table S3,
p < 0.05 for all comparisons after adjustment)
1

The variables in this table were log transformed for modeling (Additional file 1: Table S3). Comparisons across all 4 phenotypes were performed using the Kruskal–
Wallis test, the χ2 test, or the Fisher’s exact test (Additional file 1: Table S3. p < 0.05 for all comparisons after adjustment)

2

Indicates SIRS criteria ranging from 0 to 4 including abnormal heart rate, respiratory rate, temperature, and white blood cell count

3

OFI is an integer score reflecting the number of organ failures. Scores are either 0 or 1 for cardiovascular, hepatic, hematologic, respiratory, neurological,
and renal, and summed for total range of 0 to 6. Cardiovascular, need for cardiovascular agent infusion support; Pulmonary, need for mechanical ventilation
support with the ratio of the arterial partial pressure of oxygen and the fraction of inspired oxygen ( PaO2/FiO2) < 300 without this support; Hepatic, total
bilirubin > 1.0 mg/dL and alanine aminotransferase (ALT) > 100 units/L; Renal, serum creatinine > 1.0 mg/dL and oliguria (urine output < 0.5 mL/kg/h); Hematologic,
thrombocytopenia < 100,000/mm3 and prothrombin time INR > 1.5 × normal; Central Nervous System, Glasgow Coma Scale (GCS) Score < 12 in the absence of
sedatives

4

Corresponds to minimum or maximum value (as appropriate) within 6 h of hospital presentation

5

GCS ranges from 3 to 15
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Table 1 (continued)
a

The outcome characteristic of this computable phenotype is significantly higher than PedSep-A (p value < 0.05)

b

The outcome characteristic of this computable phenotype is significantly higher than PedSep-B (p value < 0.05)

c

The outcome characteristic of this computable phenotype is significantly higher than PedSep-C (p value < 0.05)

d

The outcome characteristic of this computable phenotype is significantly higher than PedSep-D (p value < 0.05)

functional assays were measured as previously described
[7–9, 15, 27].
The a priori primary outcome was hospital mortality.
The a priori secondary outcomes included development
of new or progressive MOF defined as development of
new organ failure(s) after day one [2]; PICU free days
at 30 days with 0 days given for death; length of stay in
the PICU; development of immunoparalysis [8, 9, 15,
27], thrombocytopenia-associated MOF [9, 15, 27],
sequential liver failure-associated MOF [11, 15, 27], and
macrophage activation syndrome [12, 13, 15, 27]; as well
as use of mechanical ventilation, and extracorporeal
therapies.
Derived elastic net regression results are presented
as unadjusted odds ratios. All other derived odds ratio
analyses and interactions are presented are adjusted
controlling for age, sex, ethnicity, race, and total PRISM
score. For summary analyses, the threshold for statistical
significance was less than 0.05 for two-sided tests after
adjustment for multiple testing. All analyses were
performed with R version 3.6.2.

Results
Derivation of clinical sepsis phenotypes

The derived consensus k-means clustering models [20]
found a 4-class model was the optimal fit, with phenotypes we named PedSep-A, B, C and D (Additional file 1:
Figs. S3 and S4). Consensus matrix plots and the relative
change under cumulative distribution function curve
implied little statistical gain by increasing to a 5 or 6 class
model, with penalty of overfitting. The size and characteristics of the 4-class model are given in Table 1 and
Fig. 2. They ranged in size (from 14 to 34% of the cohort)
and differed in clinical characteristics and organ dysfunction patterns (Table 1, Additional file 1: Table S3, Fig. 2,
Additional file 1: Figs. S5 and S11). With the exception of

the SIRS criteria number, all of the other 24 variables differed among the phenotypes. Compared to all other phenotypes, PedSep-A patients were younger and previously
healthy, with the lowest CRP and ferritin levels, the highest lymphocyte and platelet counts, highest heart rate,
and lowest creatinine; PedSep-B patients were most likely
to be intubated and had the lowest Glasgow Coma Scale
Score; PedSep-C patients had the highest temperature
and Glasgow Coma Scale Score, least pulmonary failure,
and lowest lymphocyte count; and PedSep-D patients
had the highest creatinine and number of organ failures,
including renal, hepatic, and hematologic organ failure,
with the lowest platelet count. On average, PedSep-B and
D patients had multiple organ failure, whereas PedSepA and C patients did not. Ferritin levels were highest in
PedSep-C and PedSep-D distinguishing them from PedSep-A and B (Table 1, Additional file 1: Table S3, Fig. 2,
Additional file 1: Figs. S5 and S11).
Correlation of phenotypes with diagnoses

Differences were noted among the derived phenotypes in diagnoses including leukemia (PedSep-D and
C > PedSep-A and B; PedSep-B > PedSep-A), inflammatory bowel disease (PedSep-D > PedSep-A and B), chromosomal abnormality (PedSep-D > PedSep-C), metabolic
disease (PedSep-B > PedSep-C and D), cardiovascular
disease + postoperative status (PedSep-D > PedSep-C),
short gut syndrome (PedSep-C > PedSep-A), and acute
bronchiolitis (PedSep-A > PedSep-B and C) (Additional
file 1: Tables S5 and S6, Additional file 1: Fig. S8). There
were no differences noted among the derived phenotypes
in the diagnoses of hemolytic anemia, rheumatic disease,
renal disease, diabetes, cardiovascular disease, trauma, or
liver disease.

(See figure on next page.)
Fig. 2 24-hour phenotype distribution and chord plot. In panel A, visualization of phenotypes using t-distributed stochastic neighbor embedding
(t-SNE) technique with phenotypes shown in color from the consensus k-means clustering analysis visualizes distinction among four phenotypes.
In panels B–E, each phenotype is highlighted separately and the ribbons connect to the different patterns of clinical variables and organ
system dysfunctions on the top of the circle (inflammation = low temperature, high temperature, max CRP, max ferritin; organ failure = total OFI;
pulmonary = pulmonary OFI, intubation; cardiovascular = high heart rate, low systolic blood pressure, cardiovascular OFI; renal = high creatinine,
renal OFI; hepatic = hepatic OFI; hematologic = low hemoglobin, low platelets, hematologic OFI; neurologic = Low Glasgow Coma Score Scale,
central nervous system OFI). The chords connect from an individual phenotype to a category if the group mean involvement of the variables differs
from the overall mean for the entire cohort (see Table 1) specifically lower for low temperature, systolic blood pressure, hemoglobin, platelets, and
Glasgow Coma Scale Score, but higher for all other variables
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Fig. 2 (See legend on previous page.)
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Table 2 Subsequent outcome characteristics of the four phenotypes
Characteristice

Total

PedSep-A

PedSep-B

PedSep-C

PedSep-D

No. of patients, N (%)

404 (100)

136 (34)

102 (25)

110 (27)

56 (14)

0 (0.0)

0 (0.0)

Development of subsequent MOF empirical phenotypes
SMOF, N (%)
TAMOF, N (%)

7 (1.7)
37 (9.2)

a

0 (0.0)

6 (5.9)

a

1 (0.9)

6 (10.7)a,b,c

3 (2.7)

28 (50.0)a,b,c
22 (39.3)a

IPMOF, N (%)

85 (21.0)

12 (8.8)

29 (28.4)

MAS, N (%)

24 (5.5)

0 (0.0)

3 (2.9)

2 (1.8)

19 (33.9)a,b,c

117 (29.0)

28 (20.6)

25 (24.5)

32 (29.1)

32 (57.1)a,b,c

Bacterial infection, N (%)

141 (34.9)

43 (31.6)

33 (32.4)

45 (40.9)

20 (35.7)

Viral infection, N (%)

114 (28.2)

60 (44.1)b,c,d

21 (20.6)

24 (21.8)

9 (16.1)

NPMOF, N (%)

22 (20)

Infections

Fungal infection, N (%)

4 (1.0)

0 (0.0)

1 (1.0)

0 (0.0)

3 (5.4)

Culture negative, N (%)

177 (43.8)

47 (34.6)

52 (51.0)

50 (45.5)

28 (50.0)

51 (12.6)

10 (7.4)

6 (5.9)

22 (20.0)a,b

13 (23.2)a,b

Sites of infectionsf
Blood, N (%)

a,c,d

Lung, N (%)

76 (18.8)

28 (20.6)

29 (28.4)

12 (10.9)

7 (12.5)

Urine, N (%)

16 (4.0)

4 (2.9)

5 (4.9)

6 (5.5)

1 (1.8)

366 (90.6)

134 (98.5)c

101 (99.0)c

79 (71.8)

52 (92.9)c

ECMO, N (%)

30 (7.4)

5 (3.7)

9 (8.8)

6 (5.5)

10 (17.9)a

CRRT, N (%)

52 (12.9)

1 (0.7)

7 (6.9)

7 (6.4)

37 (66.1)a,b,c

Organ support
MechVent, N (%)

Anti-inflammatory therapies of interest
Decadron, N (%)
Methylprednisolone, N (%)

94 (23.3)

50 (36.8)c,d

22 (21.6)

14 (12.7)

8 (14.3)

117 (29.0)

54 (39.7)b

23 (22.5)

24 (21.8)

16 (28.6)
16 (28.6)a

IVIG, N (%)

51 (12.6)

6 (4.4)

10 (9.8)

19 (17.3)a

IVIG + Methylprednisolone

23 (5.7)

3 (2.2)

4 (3.9)

9 (8.2)a

7 (12.5)a

25 (6.2)

5 (3.7)

4 (3.9)

4 (3.6)

12 (21.4)a,b,c

Plasma exchange + ECMO

6 (1.5)

1 (0.7)

1 (1.0)

1 (0.9)

Plasma exchange, N (%)

3 (5.4)

Outcome

Length of stay, median (IQR), d
Mortality, N (%)
PICU free days, median (IQR), d

9.0 (5.0–17.)
45 (11.1)
20.0 (8.0–25.0)

9.0 (5.8–15)c

10.5 (5.3–17)c

3 (2.2)

a

12 (11.7)
d

21.0 (14.8–24.0)

12.5 (7–26.5)c

6 (2.3–15)

a

19 (33.9)a,b,c

11 (10.0)
d

19.0 (9.8–24.0)

a,b,d

24.0 (13.3–27)

4.5 (0.0–21.0)

SMOF sequential liver failure-associated multiple organ failure, TAMOF thrombocytopenia-associated multiple organ failure, IPMOF immunoparalysis-associated
multiple organ failure, MAS Macrophage Activation Syndrome, NPMOF new or progressive multiple organ failure, IQR interquartile range, MechVent mechanical
ventilation, ECMO extracorporeal membrane oxygenation, CRRT continuous renal replacement therapies, IVIG intravenous gamma globulin
a

The outcome characteristic of this computable phenotype is significantly higher than PedSep-A (p value < 0.05)

b

The outcome characteristic of this computable phenotype is significantly higher than PedSep-B (p value < 0.05)

c

The outcome characteristic of this computable phenotype is significantly higher than PedSep-C (p value < 0.05)

d

The outcome characteristic of this computable phenotype is significantly higher than PedSep-D (p value < 0.05)

e

Comparisons across all 4 computable phenotypes were performed using the Kruskal–Wallis test, the χ2 test, or the Fisher’s exact test (Additional file 1: Table S3,
p < .05 for all comparisons after adjustment)

f

Obtained at the first 3 days

Correlation of phenotypes with biomarker profiles

The inflammatory biomarker profiles differed across
the four derived computable phenotypes. Inflammation evidenced by cytokine signature increased, and
immune response (whole blood ex vivo TNF response
to endotoxin) and coagulation function (ADAMTS13
activity) decreased going across PedSep-A, B, C, and D

(Additional file 1: Tables S7 and S8, Fig. 3, Additional
file 1: Fig. S10). PedSep-A showed the least inflammation with the lowest M-CSF, IL-8, IL-6, sCD163, MCP1/
CCL2, ferritin, C-reactive protein, IL-10, IL-22, IL-18,
IL-18BP, and MIP 1α levels overall; lower CXCL9
than PedSep-C and D; lower IL-17a than PedSepB and C; lower IP10/CXCL10 than PedSep-C; and
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Fig. 3 Ratio of inflammatory biomarkers according to 24-h phenotypes. The cytokine heatmap shows the log ratio of the median biomarker
values for various markers of the host response and their hierarchical cluster relationships. Red represents a greater median biomarker value for that
phenotype compared with the median for the entire study cohort, whereas blue represents a lower median biomarker value compared with the
median for the entire study cohort. For example, M-CSF is lower in PedSep-A than the entire study cohort and is higher in PedSep-D than the entire
study cohort

lower IL2Ra than PedSep-D. PedSep-A had the best
immune and coagulation function with normal whole
blood ex vivo TNF response to endotoxin (> 200 pg/
mL) and ADAMTS 13 activity. In contrast, PedSep-D
had the most profound inflammatory response with
highest M-CSF, IL-8, SCF, sCD163, IL-16, IL-10, TNF,
and MIP1α levels, and thrombotic microangiopathic
response with lowest ADAMTS13 activity decreased
to < 57% of control with thrombocytopenia. Consistent with this increased inflammation response, the
macrophage inhibitor TRAIL was reduced in PedSepD compared to PedSep-C. PedSep-D also had higher
CXCL9 then PedSep-B but not PedSep-C.

Relationship with infection, organ support needs,
and hospital mortality

PedSep-A had more viral infections, PedSep-B had
more pneumonia, and PedSep-C and D had more
blood infections (Table 2, Additional file 1: Table S9,
Additional file 1: Fig. S9). Patients in PedSep-C had the
least mechanical ventilation and the shortest length of
stay. Patients in PedSep-D required more extracorporeal
membrane oxygenation than in PedSep-A, and the most
continuous renal replacement therapy (CRRT) overall.
PedSep-A patients required the least CRRT. PICU free
days were highest in PedSep-C and lowest in PedSep-D
(Table 2, Additional file 1: Table S9).
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Fig. 4 Comparison of relationships of 25 variables to mortality in PedSep-A, B, C, and D. In all panels, the variables are standardized such that all
means are scaled to 0 and SDs to 1. A value of 1 for the standardized variable value (x-axis) signifies that the mean value for the phenotype was 1
SD higher, or lower for − 1, than the mean value for the phenotypes shown in the graph as a whole. CNS central nervous system, CRPH C-reactive
protein, GCS Glasgow Coma Scale, Hemat hematologic, Intubate intubation with endotracheal tube, OFI organ failure index, Post-Op post-surgery,
Pulm pulmonary, Temp temperature, SBP systolic blood pressure, Chronic illness those who are not recorded as previous healthy, Ethnicity value is
higher with more non-Hispanics in group, Sex value is higher with more males in group

Hospital mortality was 2% in PedSep-A, 12% in
PedSep-B, 10% in PedSep-C, and 34% in PedSep-D
(PedSep-B vs. A Adj OR 4.11 95% CI [1.11–19.96]
p = 0.048; PedSep-C vs. A Adj OR 4.35 95% CI [1.23–
20.43] p = 0.034; PedSep-D vs. A Adj OR 17.25 95%
CI [4.93–92.06] p = 4.42E−05; PedSep-D vs B Adj OR
4.20 95% CI [1.84–9.97] p = 0.0008; and PedSep-D vs.

C Adj OR 3.97 95% CI 1.62–10.14] p = 0.003) (Table 2,
Additional file 1: Table S9).
The derived mortality curves show all deaths in
PedSep-A occurred before seven days, whereas
deaths in PedSep-B, C, and D continued to accrue
after seven days (Fig. 5, Additional file 1: Fig. S13).
Mortality was associated with Glasgow Coma Scale
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Fig. 5 Organ failure and mortality curves over 28 days among 24-h phenotypes. Number of organ failures and mortality according to PedSep-A,
B, C, and D phenotype over 28 days. Both short-term mortality (panel A) and organ failure (panel B) show significant differences by phenotype
(p < 0.001). The mean numbers of organ failures and 95% confidence intervals (CI) are calculated each day by non-nested observation, where we
do not carry forward the OFI at the time the patient leaves the PICU alive or dead. As a reference for patients at risk for Panel B, Panel C shows the
number of children remaining in the PCU at day 0, 7, 14, 21, and 28

Score < 12, decreased TNF and IL-2Ra levels, and
increased MCP3 levels in PedSep-A; increased IL-6,
IL-8, and MCP1/CCL2 levels in PedSep-B; high ferritin, lymphopenia, lower temperature, higher blood
pressure, and increased IL-8 levels in PedSep-C; and

hyperferritinemia, chronic illness, increased MIP-1α,
IL-8, and IL-10 levels, and decreased IL-18 and sFASL
levels in PedSep-D (Fig. 4, Additional file 1: Tables S9–
S11, Additional file 1: Fig. S12).
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Fig. 6 Heterogeneous treatment interactions and mortality risks among the phenotypes. Heatmap of Elastic Net Regression analysis shows the
association between 14 individual therapies (diagonal values) and their 91 combination interactions (total cells = 105) with mortality in PedSep-B,
C, and D among children who received anti-inflammatory therapies. The PedSep-A phenotype is not presented due to limited number of deaths.
Blank cells have no patients. Values in each cell represent odds ratios of mortality, where 1 represents no association with mortality. Color in each
cell represents direction of effect, where red represents mortality direction, green represents survival direction. Cells located at the diagonal are
odds ratio of association from the 14 individual therapies. The other cells represent the mortality odds ratio of combinations of these therapies
compared to all other combinations. For example, survivors in PedSep-D phenotype are less likely to be treated with IVIG than non-survivors (red),
whereas survivors in PedSep-D are more likely to be treated with combined IVIG + methylprednisolone (green). This machine analysis method does
not allow calculation of confidence intervals

Relationship with development of immunoparalysis,
TAMOF, SMOF, and MAS

On average, children in PedSep-A and PedSep-C
developed less than two organ failures; children in
PedSep-B developed more than two organ failures;
and children in PedSep-D developed more than three

organ failures over 28 days (Fig. 5, Additional file 1: Fig.
S13). Children in PedSep-D had the highest proclivity
to develop immunoparalysis (Adj OR 2.40 95% CI
[1.25–4.53; p = 7.20E-03), new and progressive organ
failure (Adj OR 4.03 95% CI [2.19–7.55]; p = 9.48E-06),
thrombocytopenia-associated MOF (Adj OR 47.51 95%
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CI [18.83–136.83]; p = 1.25E-14), sequential liver failureassociated MOF (Adj OR 61.56 95% CI [8.93–1,282.58];
p = 3.80E-04), and macrophage activation syndrome
(Adj OR 38.63 95% CI [13.26–137.75]; p = 4.61E-10).
Immunoparalysis- and thrombocytopenia-associated
MOF also occurred more commonly in children in
PedSep-B and D compared to those in PedSep-A
(Table 2, Additional file 1: Fig. S14).
Heterogeneous treatment interactions with therapies

All 3 organ support therapies and 11 of 41 antiinflammatory therapies were associated with outcome
in univariable analysis (Additional file 1: Tables S12 and
S13, Additional file 1: Fig. S15) among the children who
received anti-inflammatory therapies and were included
in the derived exploratory elastic net regression analysis
(Fig. 6, Additional file 1: Fig. S15) [28]. This was not
performed in PedSep-A because mortality was very low
at 2%. The constructed elastic net regression heatmaps
visualize heterogeneous mortality association patterns
across PedSep-B, C, and D (Fig. 6). Unadjusted mortality
odds ratios < 0.1 with use of anti-inflammatory agents
were not observed with any single therapy; however,
unadjusted interactions < 0.1 were observed with use
of methylprednisolone and IVIG together, and in
extracorporeal membrane oxygenator patients receiving
plasma exchange, in PedSep-D (Fig. 6).
Combined use of methylprednisolone plus IVIG
was more common in PedSep-C and D than in A and
B (Table 2). Methylprednisolone was administered on
median day 1 (25th–75th % tile days 1–3) for a median
duration of 5 days (25th–75th % tile 2–7 days). IVIG
was administered on median day 2 (25th–75th% tile
day 1–7) for a median duration of 1 day (25th-75th %
tile 1–3 days) (Additional file 1: Table S13). Neither
methylprednisolone nor IVIG treatment alone,
nor the combination, was associated with reduced
odds of mortality in adjusted logistic regression
modeling (Additional file 1: Table S14, S15, and S16).
The interaction term < 0.1 identified in elastic net
regression analysis between methylprednisolone
and IVIG therapies in PedSep-D patients remained
statistically significant in logistic regression analysis
(Methylprednisolone * IVIG interaction = 0.03; 95% CI
[0.00058–0.66] p = 0.04) interpreted as meaning that
the association of IVIG with mortality was modified
by exposure to methylprednisolone in PedSep-D
patients (Additional file 1: Tables S14 and S15). There
was also a significant interaction between PedSep-D
membership and use of combined methylprednisolone
plus IVIG therapy in logistic regression analysis
(PedSep-D * Methylprednisolone + IVIG combination
interaction = 0.04 95% CI [0.001–0.56] p = 0.026)
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interpreted as meaning that the mortality association
with exposure to combined methylprednisolone
plus IVIG use is modified by PedSep-D membership
(Additional file 1: Tables S16 and S17). Plasma exchange
was most commonly used in PedSep-D (Table 2). The
interaction term < 0.1 identified in elastic net regression
modeling between ECMO and plasma exchange use was
not statistically significant in logistic regression modeling
(ECMO * plasma exchange interaction = 0.02 95% CI
[0.000165–0.97] p = 0.06) (Additional file 1: Table S15).

Discussion
Machine learning analysis of a priori elements from the
extant PHENOMS study derived four computable 24-h
phenotypes meeting three of five ‘path forward’ criteria
[25] providing impetus for their further evaluation in
new pediatric sepsis studies. The derived computable
phenotypes demonstrated clinical relevance with
differences in types of presenting diagnoses, infections,
organ failures, need for organ support therapies,
outcomes, and proclivity to development of TAMOF
and MAS. Derived consensus k-means clustering and
t-SNE analyses demonstrated that the computable
phenotypes are nonsynonymous. The differences in
cytokine profiles provide biological plausibility for
these derived computable phenotypes having different
inflammation responses, highlighted in PedSep-D by
decreased ADAMTS13 with TAMOF and increased
MIP 1α with MAS. Exploratory modeling of interactions
between therapies among patients receiving antiinflammatory
treatments,
derived
computable
phenotypes, and mortality demonstrated no reduction
in mortality odds with methylprednisolone, IVIG or
the combination; however, it identified a signal for
methylprednisolone affecting the relationship of IVIG
therapy to outcome in PedSep-D patients. We speculate
that this interaction is reminiscent of the report that
addition of methylprednisolone to IVIG improves
cardiac function in children with COVID19-related
multisystem inflammatory syndrome (MIS-C) compared
to IVIG alone [30]. The very wide confidence intervals
provide impetus to further evaluate this interaction
signal in larger sample sizes using new study cohorts.
We are presently assessing treatment responsiveness
and reproducibility of the four derived phenotypes
in our NICHD network’s 1000 patient Personalized
Immunomodulation in Pediatric Sepsis and Multiple
Organ Dysfunction trial testing interleukin 1 antagonist
protein for hyper-inflammatory sepsis; and, also in the
observational 500 patient Second Argentinian Pediatric
Sepsis Epidemiology Study (PI Roberto Jabornisky).
PedSep-A is characterized by younger previously
healthy children with respiratory failure and the least
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increased inflammation. This resembles the adult α
phenotype in the SENECA trial [20], and also the MARS
3 and sepsis response signature 2 endotypes, which found
predominant expression of adaptive immune and B-cell
developmental pathways [31–33]. Mortality in PedSep-A
was low at 2% and did not increase after 7 days, making
anti-inflammatory clinical trials directed to survival less
feasible.
PedSep-B is characterized by multiple organ failure
requiring intubation for more severe respiratory failure,
shock, and central nervous system dysfunction with
increased C-reactive protein levels and 12% mortality.
This is reminiscent of children reported in the Life After
Pediatric Sepsis Evaluation study [34]; the shock with
hypoxia phenotype in adult sepsis-induced MOF [35];
and the severe hypoxia, altered mental status, and shock
phenotype in pediatric MOF [36].
PedSep-C is distinguished by cardiovascular failure
and relative absence of need for intubation (14%)
with the least pulmonary failure (34%) and need for
mechanical ventilation (71%), in the presence of elevated
C-reactive protein, high ferritin, and lymphopenia, with
10% mortality. This is reminiscent of the Toxic Shock
(TSS)—Kawasaki syndrome phenotype currently being
considered as PMIS/MIS-C syndrome [30, 37–40].
Similar to TSS and Kawasaki’s, our PedSep-C patients
showed elevated IL-17a and IP10/CXCL10 levels [41, 42].
PedSep-D patients had cardiovascular, respiratory,
liver, renal, hematologic, and neurologic dysfunction
with 34% mortality; clinical features shared by the adult
δ phenotype characterized in the SENECA study using
electronic health record criteria for Sepsis-3 [20]; the
shock with thrombocytopenia pediatric MOF phenotype
[36]; and previously reported subclasses including the
hyperinflammatory sub-phenotype reported in acute
respiratory distress syndrome, a condition commonly
related to sepsis [43–45]. It also resembles sepsis
endotypes derived using transcriptomic analyses of
circulating immune cells, specifically the inflammopathic
cluster known as sepsis signature 1, or the Molecular
Diagnosis and Risk Stratification of Sepsis [MARS] 2
cluster [31–33].
PedSep-D
is
specifically
characterized
by
hyperferritinemic
(ferritin > 500
ng/mL),
thrombocytopenic (platelet count < 100 K) multiple
organ failure with the highest likelihood of new or
progressive multiple organ failure accruing mortality
after 7 days and the lowest number of PICU free days.
PedSep-D membership identifies children with the
highest proclivity for decreased ADAMTS 13 activity
with thrombocytopenia-associated MOF, and increased
MIP 1α with macrophage activation syndrome.
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There are limitations to consider in this post hoc
machine learning analysis of the parent PHENOMS
study and its inherent selection bias risks. Although the
PHENOMS study represents the largest longitudinal
multiple center pediatric sepsis-induced MOF cohort
with concomitant CRP and ferritin levels available [15],
it is small compared to adult standards because sepsis
occurs 15 times more commonly in adults than in
children. Definitions of pediatric sepsis and organ failures
are also evolving and behind the changes in adult sepsis.
Definitions of sepsis and organ failure were necessarily
limited to those used in the extant study. Only 25 out
of 52 available clinical and laboratory variables available
in this parent study had < 20% missingness without
covariance and were included in the machine learning
derivation. Only 33 additional biomarkers [8, 9, 11, 27, 45]
were performed to assess biological plausibility for the
computable phenotypes having different inflammatory
responses. Lactate was not recorded and may be an
important missing variable [46]. Interactions could
only be assessed for those therapies given by bedside
clinicians in a ‘natural experiment’ setting. Our models
did not capture all confounders, comorbidities, therapies
used, reasons for therapies, or site differences in clinical
practice. Furthermore, combined methylprednisolone
plus IVIG and ECMO plus plasma exchange therapies
were rarely administered. Reproducibility of the derived
computable phenotypes cannot be assessed in a single
extant multiple center resource rich study. We are
presently assessing reproducibility in two ongoing
independent cohort studies.

Conclusions
Machine learning analysis in the PHENOMS study
derived four novel computable 24-h pediatric sepsis
phenotypes providing a computer tool (www.pedse
psis.pitt.edu) that enables clinical researchers to
perform bedside identification of an individual
patient’s computable phenotype membership. If proven
reproducible, then PedSep-D membership appears most
optimal for identifying children for early enrollment
in personalized anti-inflammatory trials targeting
thrombocytopenia-associated MOF and macrophage
activation syndrome.
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